SAN FRANCISCO, July 10, 2018 /PRNewswire/ --
The global ovarian cancer drugs market size is expected tobe valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption
(Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )
Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all female deaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.
Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.
Browse full research report with TOC on "Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors) , By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022" at: https://www.grandviewresearch.com/industry-analysis/ovarian-cancer-drugs-market
Further Key Findings From the Report Suggest:
Browse related reports by Grand View Research:
Grand View Research has segmented the global ovarian cancer drugs market based on therapeutic class and region:
Explore the BI enabled intuitive market research database, The Grand Library, by Grand View Research, Inc.
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc. Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: email@example.com
SOURCE Grand View Research, Inc.
Subscribe to our Free Newsletters!
Complex regional pain syndrome (CRPS) is rare chronic pain disorder usually involving an arm or ...
Polyarthritis refers to pain in four or more joints simultaneously due to various causes ranging ...
Gardner or Gardner''s syndrome, also known as familial adenomatous polyposis (FAP), is an autosomal ...View All